Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Recurrent Mixed Phenotype Acute Leukemia: early-phase trial registry
4 of 8 indexed Recurrent Mixed Phenotype Acute Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Recurrent Mixed Phenotype Acute Leukemia: 8 US clinical trials tracked, 4 recruiting.
Recurrent Mixed Phenotype Acute Leukemia is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Fred Hutchinson Cancer Center, running 3 of these trials.
Enrollment posture brief
Registry condition recurrent-mixed-phenotype-acute-leukemia
OPEN 4 | RECR 50% | LATE 0 | EARLY 8 | RANK #2176 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
Recurrent Mixed Phenotype Acute Leukemia lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Recurrent Mixed Phenotype Acute Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Recurrent Mixed Phenotype Acute Leukemia is recruiting above its size-band peers.
4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Recurrent Mixed Phenotype Acute Leukemia research.
Fred Hutchinson Cancer Center accounts for 3 of 8 trials (37.5%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Recurrent Mixed Phenotype Acute Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 8 trials that report a genuine target (sentinel values excluded). 8 of those (100%) plan for fewer than 100 participants.
-
Recurrent Mixed Phenotype Acute Leukemia research is mostly interventional.
8 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
Fred Hutchinson Cancer Center
NCT03128034
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
NCT06928662
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT03670966
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
OHSU Knight Cancer Institute
NCT04872790
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
Children's Oncology Group
NCT05761171
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
NCT02879695
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane
National Cancer Institute (NCI)
NCT05146739
Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia
M.D. Anderson Cancer Center
NCT02135874
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Recurrent Mixed Phenotype Acute Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Recurrent Mixed Phenotype Acute Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Recurrent Mixed Phenotype Acute Leukemia page
8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Recurrent Mixed Phenotype Acute Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Fred Hutchinson Cancer Center sponsors the most Recurrent Mixed Phenotype Acute Leukemia trials on record, review their full trial history before evaluating a specific study. See Fred Hutchinson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Recurrent Mixed Phenotype Acute Leukemia condition card totals 8 registered trials; most-linked intervention Cytarabine; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.